These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 11221885

  • 1. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
    Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ.
    Cancer Res; 2001 Feb 01; 61(3):931-4. PubMed ID: 11221885
    [Abstract] [Full Text] [Related]

  • 2. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
    Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, Takahashi T.
    Cancer Res; 2001 Nov 15; 61(22):8331-9. PubMed ID: 11719467
    [Abstract] [Full Text] [Related]

  • 3. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
    Zhao S, Venkatasubbarao K, Li S, Freeman JW.
    Cancer Res; 2003 May 15; 63(10):2624-30. PubMed ID: 12750289
    [Abstract] [Full Text] [Related]

  • 4. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
    Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T.
    Mol Carcinog; 2005 Dec 15; 44(4):233-41. PubMed ID: 16163707
    [Abstract] [Full Text] [Related]

  • 5. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y, Kyprianou N.
    Cancer Res; 1999 Mar 15; 59(6):1366-71. PubMed ID: 10096572
    [Abstract] [Full Text] [Related]

  • 6. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ.
    Cancer Res; 2002 Nov 01; 62(21):6108-15. PubMed ID: 12414635
    [Abstract] [Full Text] [Related]

  • 7. Trichostatin A-induced TGF-beta type II receptor expression in retinoblastoma cell lines.
    Kashiwagi Y, Horie K, Kanno C, Inomata M, Imamura T, Kato M, Yamamoto T, Yamashita H.
    Invest Ophthalmol Vis Sci; 2010 Feb 01; 51(2):679-85. PubMed ID: 19737884
    [Abstract] [Full Text] [Related]

  • 8. Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
    Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M, Yamada K, Inoue M.
    Gynecol Oncol; 2005 Sep 01; 98(3):427-33. PubMed ID: 15993480
    [Abstract] [Full Text] [Related]

  • 9. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
    Parekh TV, Gama P, Wen X, Demopoulos R, Munger JS, Carcangiu ML, Reiss M, Gold LI.
    Cancer Res; 2002 May 15; 62(10):2778-90. PubMed ID: 12019154
    [Abstract] [Full Text] [Related]

  • 10. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG.
    J Cell Physiol; 1998 Aug 15; 176(2):424-34. PubMed ID: 9648930
    [Abstract] [Full Text] [Related]

  • 11. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
    Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K, Miyazawa K.
    Cancer Res; 2003 Nov 15; 63(22):7791-8. PubMed ID: 14633705
    [Abstract] [Full Text] [Related]

  • 12. Loss of functional transforming growth factor (TGF)-beta type II receptor results in insensitivity to TGF-beta1-mediated apoptosis and Epstein-Barr virus reactivation.
    Fukuda M, Kurosaki H, Sairenji T.
    J Med Virol; 2006 Nov 15; 78(11):1456-64. PubMed ID: 16998876
    [Abstract] [Full Text] [Related]

  • 13. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T, Kobayashi H, Wakahara K, Matsuzaki H, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T.
    FEBS Lett; 2004 Oct 22; 576(3):408-16. PubMed ID: 15498571
    [Abstract] [Full Text] [Related]

  • 14. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling.
    Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB.
    Cancer Res; 2003 Mar 15; 63(6):1371-6. PubMed ID: 12649201
    [Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
    Tong M, Ding Y, Tai HH.
    Biochem Pharmacol; 2006 Sep 14; 72(6):701-9. PubMed ID: 16844092
    [Abstract] [Full Text] [Related]

  • 16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 17. The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
    Kim IY, Zelner DJ, Lee C.
    Exp Cell Res; 1998 May 25; 241(1):151-60. PubMed ID: 9633523
    [Abstract] [Full Text] [Related]

  • 18. Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression.
    Jong HS, Lee HS, Kim TY, Im YH, Park JW, Kim NK, Bang YJ.
    Biochem Biophys Res Commun; 2002 Mar 29; 292(2):383-9. PubMed ID: 11906173
    [Abstract] [Full Text] [Related]

  • 19. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
    Chen A, Davis BH, Sitrin MD, Brasitus TA, Bissonnette M.
    Am J Physiol Gastrointest Liver Physiol; 2002 Oct 29; 283(4):G864-74. PubMed ID: 12223346
    [Abstract] [Full Text] [Related]

  • 20. Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
    Periyasamy S, Ammanamanchi S, Tillekeratne MP, Brattain MG.
    Oncogene; 2000 Sep 21; 19(40):4660-7. PubMed ID: 11030155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.